On October 18, 2018 Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported that the company will host a conference call and live webcast on Thursday, November 1, 2018 at 8:00 a.m. ET to report its third quarter financial results and other business highlights (Press release, Agios Pharmaceuticals, OCT 18, 2018, http://investor.agios.com/news-releases/news-release-details/agios-webcast-conference-call-third-quarter-2018-financial [SID1234530260]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 5285068. The webcast will be archived and made available for replay on the company’s website beginning approximately two hours after the event

On October 18, 2018 Bexion Pharmaceuticals, Inc., a clini cal stage biotechnology company focused on developing innovative cures for cancer, reported that Dr. Ray Takigiku, Founder and CEO of the Company presented recently at the 15 th Annual BioNetwork Partnering Summit, held in Laguna Nigel, CA from October 10 – 12, 2018 (Press release, Bexion, OCT 18, 2018, View Source [SID1234530294]). Chosen by the National Cancer Institute as part of its SBIR Investor Initiatives program, Bexion was among a select group of companies th at the N CI sponsored to present at this annual biotech industry financial partnering forum.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Over 200 se nior decision makers in pharma and biotech deal making attend ed the conference to pursue relationships for partnerships and investment opportunities.

Dr. Takigiku presented the Bexion story to the audience and participated in numerous one to one meetings with pharma organizations.

About NCI SBIR Investor Initiatives Program

Through the Investor Initiatives Program, the National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Development Center connects NCI SBIR funded companies wi th potential investors and strategic partners to continue the research and commercialization efforts initially funded by NCI. Companies must apply and are selected by a panel of independent experts including over 50 Venture Capital organizations and potent ial strategic partners.

On October 18, 2018 Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reported that patient treatments have begun in the Company’s second global US registration trial investigating Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) in the treatment of patients with intrahepatic cholangiocarcinoma (ICC) (Press release, Delcath Systems, OCT 18, 2018, View Source;p=RssLanding&cat=news&id=2372259 [SID1234530000]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The University of Tennessee Health Science Center (UTHSC) in collaboration with Methodist University Hospital (MUH) and West Cancer Center (WCC) in Memphis, Tennessee have enrolled the trial’s first patient and treatments have begun by a team led by Dr. Evan S. Glazer. Dr. Glazer, a board certified surgical oncologist, is the principal investigator for the trial at the UTHSC/MUH/WCC location.

The trial, entitled A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) in Patients with Intrahepatic Cholangiocarcinoma, (the ALIGN Trial) will seek to enroll approximately 295 ICC patients at approximately 40 clinical sites in the U.S. and Europe.

"ICC is a deadly form of liver cancer, and the current treatment options have only shown very limited benefit," said Dr. Evan Glazer, "Our team is encouraged by the initial data available for Melphalan/HDS and are pleased to participate in this trial to explore this therapy’s potential as a new treatment option for these patients. We are most excited by the multi-disciplinary approach that this trial takes to help our patients."

"We are delighted to be working with Dr. Glazer and the team in Memphis to initiate The ALIGN Trial," said Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems. "In this orphan population where there exists a large unmet need, this trial provides us with a potential second pathway to commercial drug approval in the United States, and if successful we believe will be an important value driver for Delcath."

On October 18, 2018 DXC Technology (NYSE: DXC), the world’s leading independent, end-to-end IT services company, reported that it will release financial results for the second quarter of fiscal 2019 on Tuesday, November 6, 2018, at approximately 4:15 p.m. Eastern Standard Time (EST) (Press release, DynPort Vaccine Company, OCT 18, 2018, View Source [SID1234529972]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DXC Technology senior management will host a conference call and webcast on the same day at 5 p.m. EST. The dial-in number for domestic callers is (877) 260-1479. Callers who reside outside of the United States should dial +1 (334) 323-0522. The passcode for all participants is 4189723. The webcast audio and any presentation slides will be available on DXC Technology’s Investor Relations website.

A replay of the conference call will be available from approximately two hours after the conclusion of the call until November 13, 2018. Replay numbers can be found at the following link. The replay passcode is also 4189723.

DXC Technology Investor Day

DXC Technology will host its 2018 Investor Day on Thursday, November 8, 2018 in New York City, with presentations beginning at approximately 9:30 a.m. Eastern Standard Time (EST).

A webcast of the Investor Day and any presentation slides will be available on DXC’s Investor Relations website. The webcast will begin on Thursday, November 8, 2018 at 9:30 a.m. EST at View Source

On October 17, 2018 OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, reported that William Annett, President and Chief Executive Officer, will provide a corporate overview at the BIO Investor Forum, being held October 17-18, 2018 in San Francisco, California (Press release, BioTime, OCT 17, 2018, View Source;p=RssLanding&cat=news&id=2372038 [SID1234530002]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OncoCyte Corporation Presentation Details:
Date: Thursday, October 18
Time: 10:45am Pacific Time/1:45pm Eastern Time
Location: Westin St. Francis Hotel, Yorkshire Room
Webcast: http://www.veracast.com/webcasts/bio/investorforum2018/94207593256.cfm